TrueBinding, Inc.

TrueBinding, Inc. is a privately held, clinical-stage biotherapeutics company headquartered in Menlo Park, California, in the United States. Founded in 2016 by George Hong, the company describes itself as pioneering a broad-spectrum healthspan platform aimed at resolving the fundamental drivers of chronic inflammation and age-related decline rather than treating downstream symptoms. Its core scientific focus is Galectin-3 (Gal-3), a protein the company characterizes as one of the body's 'master switches' of disease and aging. By neutralizing Gal-3, TrueBinding aims to interrupt toxic feedback loops involving neuroinflammation, protein aggregation, and systemic tissue damage. The company's lead investigational product is TB006, a monoclonal antibody directed against Galectin-3. TrueBinding is developing TB006 across several therapeutic areas, with neurodegeneration — including Alzheimer's disease and Parkinson's disease — positioned as the most demanding test of the platform. The company's stated rationale is that if Gal-3 inhibition works in the brain, where the blood-brain barrier and microglial complexity create a highly restrictive environment, it would de-risk the broader potency of the systemic antibody for other indications such as stroke, fibrosis, and oncology. TrueBinding has completed a Phase 1b/2a clinical trial of TB006 in Alzheimer's disease. According to the company, topline data from a one-month treatment regimen showed improvements in the Clinical Dementia Rating-Sum of Boxes (CDR-SB), suggesting the potential to slow or reduce clinical decline, with key secondary endpoints consistent with the primary findings. The FDA has authorized an Expanded Access Program (EAP) for investigational TB006, permitting eligible patients with dementia, including Alzheimer's disease, to request access to the product outside of clinical trials. The program is intended for patients with serious or life-threatening conditions who cannot participate in clinical studies and lack satisfactory alternative treatment options. TrueBinding operates both a USA Expanded Access Program and a Global Expanded Access Program, and the FDA renewed the program in April 2026. TrueBinding is a private company and does not disclose a stock ticker. Its leadership combines drug-development experience with clinical and scientific expertise. Founder George Hong has a background in healthcare investment, with strategic investments in companies such as Ceribell, Neurovasc, Arrinex, Devoro, and Lucira. The management team also includes Alan K. Jacobs, MD, as Chief Medical Officer, whose prior roles include Satellos Biosciences, Boston Pharmaceuticals, Immunovant, and Sanofi Genzyme, and Rajesh Pahwa, MD, a Parkinson's disease specialist at the University of Kansas Medical Center. The company positions itself at the intersection of inflammation biology and longevity science, with the long-term vision of extending human healthspan.

TrueBinding, Inc. was founded in 2016 by George Hong, who had previously built a career in healthcare investment, with strategic investments in companies such as Ceribell, Neurovasc, Arrinex, Devoro, and Lucira. The company was established in Menlo Park, California, in the United States, and set out to build a biotherapeutics platform focused on the biology of aging. From its inception, TrueBinding organized its research around Galectin-3 (Gal-3), a protein it describes as one of the body's 'master switches' of disease and aging. The company's proprietary TrueBinding platform was designed as a discovery engine to identify and neutralize such upstream drivers of chronic inflammation, rather than chasing downstream symptoms. This approach positioned the company within the emerging field of inflammaging — the study of how chronic, low-grade inflammation contributes to age-related decline. The company's lead asset, TB006, is an investigational monoclonal antibody that neutralizes Galectin-3. TrueBinding has pursued a broad-spectrum development strategy for TB006, targeting neurodegeneration (Alzheimer's disease and Parkinson's disease), stroke, fibrosis, and oncology. The company has articulated a deliberate scientific rationale for prioritizing neurodegeneration: because the blood-brain barrier and microglial complexity make the brain the most difficult environment in which to resolve chronic inflammation, demonstrating Gal-3 inhibition there would effectively de-risk the broader potency of the systemic antibody. TrueBinding completed a Phase 1b/2a clinical trial of TB006 in Alzheimer's disease. According to the company, topline data from a one-month treatment regimen showed improvements in the Clinical Dementia Rating-Sum of Boxes (CDR-SB), indicating the potential to slow or reduce clinical decline, with key secondary endpoints consistent with the primary findings. The company has continued clinical development of TB006 while also pursuing regulatory pathways for patient access. The FDA authorized an Expanded Access Program (EAP) for investigational TB006, allowing eligible patients with dementia, including Alzheimer's disease, to request access to the product outside of clinical trials. The program is intended for patients with serious or life-threatening conditions who are unable to participate in clinical studies and who lack satisfactory alternative treatment options. TrueBinding operates both a USA Expanded Access Program and a Global Expanded Access Program. In April 2026, the FDA renewed the Expanded Access Program (NCT05959239) for TB006 in treating dementia. As of the available evidence, TrueBinding remains a private, clinical-stage company headquartered in Menlo Park, California. Its leadership team includes founder George Hong; Alan K. Jacobs, MD, as Chief Medical Officer, whose prior experience includes Satellos Biosciences, Boston Pharmaceuticals, Immunovant, and Sanofi Genzyme; and Rajesh Pahwa, MD, a Parkinson's disease specialist at the University of Kansas Medical Center. The company's stated long-term vision extends beyond treating late-stage disease to restoring immune balance and protecting cellular integrity, with the ultimate goal of extending human healthspan and longevity.

• 2026

  FDA renews Expanded Access Program (NCT05959239) for TB006 in dementia

• 2016

  TrueBinding founded by George Hong

• Completion of Phase 1b/2a clinical trial of TB006 for Alzheimer's disease; topline CDR-SB improvements reported

• FDA authorizes Expanded Access Program (EAP) for investigational TB006 in dementia

Clinical-stage biotherapeutics company pioneering a broad-spectrum healthspan platform by neutralizing Galectin-3 to resolve chronic inflammaging and age-related decline.

• TB006

  Investigational monoclonal antibody that neutralizes Galectin-3; being developed for neurodegeneration (Alzheimer's, Parkinson's), stroke, fibrosis, and oncology.

• TrueBinding platform

  Proprietary discovery engine focused on the body's 'master switches' of disease and aging, most notably Galectin-3.

1. 1TrueBindingtruebinding.com
2. 2About Us — TrueBindingtruebinding.com
3. 3TrueBinding (United States) — Wikidatawikidata.org